bioRxivImmunology
High-resolution map of the Fc-functions mediated by COVID-19 neutralizing antibodies
I. Paciello, G. Maccari, E. Pantano, E. Andreano, R. Rappuoli
Abstract
A growing body of evidence shows that Fc-dependent antibody effector functions play an important role in protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To unravel the mechanisms that drive these responses, we analyzed the phagocytosis and complement deposition mediated by a panel of 482 human monoclonal antibodies (nAbs) neutralizing the original Wuhan virus, expressed as recombinant IgG1. Our study confirmed that nAbs no longer neutralizing SARS-CoV-2 Omicron variants can retain their Fc-functions. Surprisingly, we found that nAbs with the most potent Fc-function recognize the N- terminal domain, followed by those targeting Class 3 epitopes in the receptor binding domain. Interestingly, nAbs direct against the Class 1/2 epitopes in the receptor binding motif, which are the most potent in neutralizing the virus, were the weakest in Fc-functions. The divergent properties of the neutralizing and Fc- function mediating antibodies were confirmed by the use of different B cell germlines and by the observation that Fc-functions of polyclonal sera differ from the profile observed with nAbs, suggesting that not-neutralizing antibodies also contribute to Fc-functions. These data provide a high-resolution picture of the Fc-antibody response to SARS-CoV-2 and suggest that the Fc contribution should be considered for the design of improved vaccines, the selection of therapeutic antibodies and the evaluation of correlates of protection.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies
T. Noy-Porat, A. Edri, … O. Mazor·bioRxiv·May 15, 2021
- Protective non-neutralizing mAbs Ab94 and Ab81 retain high-affinity and potent Fc-mediated function against SARS-CoV-2 variants from Omicron to XBB1.5
A. Izadi, M. Godzwon, … P. Nordenfelt·bioRxiv·Sep 29, 2023
- Role of Nonneutralizing Antibodies and Fc Effector Functions in Inhibiting SARS-CoV-2 Infection
Haiyan Sun, Adrian Esqueda, … Qiang Chen·bioRxiv·Apr 9, 2026
- Epitope-Driven Polyfunctional Divergence of SARS-CoV-2 RBD Antibodies
Pierre Rosenbaum, Cyril Planchais, … Hugo Mouquet·iSciencePeer-reviewed·Sep 1, 2026
- Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
C. N. Pierre, L. E. Adams, … K. Saunders·bioRxiv·Jul 25, 2023
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
E. S. Winkler, P. Gilchuk, … M. Diamond·bioRxiv·Dec 28, 2020